Free Trial

PTC Therapeutics (PTCT) Stock Forecast & Price Target

$38.64
-0.21 (-0.54%)
(As of 05/22/2024 ET)

PTC Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 14 Analyst Ratings

Consensus Price Target

$35.67
-7.69% Downside
High Forecast$55.00
Average Forecast$35.67
Low Forecast$23.00
TypeCurrent Forecast
5/24/23 to 5/23/24
1 Month Ago
4/24/23 to 4/23/24
3 Months Ago
2/23/23 to 2/23/24
1 Year Ago
5/24/22 to 5/24/23
Consensus Rating
Hold
Reduce
Reduce
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
5 Buy rating(s)
Hold
7 Hold rating(s)
5 Hold rating(s)
6 Hold rating(s)
5 Hold rating(s)
Sell
3 Sell rating(s)
5 Sell rating(s)
5 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$35.67$33.53$34.29$52.93
Forecasted Upside-7.69% Downside20.72% Upside15.97% Upside7.95% Upside
Get PTC Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.

PTCT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PTCT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

PTC Therapeutics Stock vs. The Competition

TypePTC TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.07
2.69
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside-7.69% Downside704.29% Upside8.71% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Recent Analyst Forecasts and Stock Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/21/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSell ➝ Sell$18.00 ➝ $26.00-33.30%
5/21/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$43.00 ➝ $53.00+34.04%
5/21/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSell ➝ Sell$18.00 ➝ $32.00-19.76%
5/20/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$35.00 ➝ $46.00+15.69%
5/20/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Brill
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Market Perform
4/29/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderweight ➝ Equal Weight$28.00 ➝ $30.00+5.01%
4/12/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$45.00+63.22%
3/1/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSector Perform ➝ Sector Perform$22.00 ➝ $28.00-7.32%
3/1/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Perform ➝ Market Perform$32.00 ➝ $30.00+6.42%
12/8/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$37.00+40.79%
10/27/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$26.00 ➝ $25.00+4.38%
10/5/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$45.00 ➝ $25.00+12.61%
9/19/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderperform ➝ Underperform$43.00 ➝ $23.00-5.27%
9/18/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Schwartz
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Target$44.00 ➝ $30.00+18.81%
7/20/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral$50.00+24.94%
5/18/2023VNET Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
3/22/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Corwin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
3/17/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$48.00-0.21%
11/1/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$44.00+16.62%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:00 AM ET.

PTCT Frequently Asked Questions

What is PTC Therapeutics's stock forecast and purchase recommendation?

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for PTC Therapeutics is $35.67, with a high forecast of $55.00 and a low forecast of $23.00. The consensus rating for PTC Therapeutics stock is Hold based on the current 3 sell ratings, 7 hold ratings and 4 buy ratings for PTCT. Learn more on PTCT's analyst rating history.

Do Wall Street analysts like PTC Therapeutics more than its competitors?

Analysts like PTC Therapeutics less than other "medical" companies. The consensus rating for PTC Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how PTCT compares to other companies.

Is PTC Therapeutics being upgraded by Wall Street analysts?

Over the previous 90 days, PTC Therapeutics's stock had 2 upgrades by analysts.

Does PTC Therapeutics's stock price have much upside?

According to analysts, PTC Therapeutics's stock has a predicted upside of 12.92% based on their 12-month stock forecasts.

What analysts cover PTC Therapeutics?

Stock Forecasts and Research Tools

This page (NASDAQ:PTCT) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners